Durezol approved to relieve pain and inflammation after ophthalmic surgery
FDA has cleared a new steroid to treat patients after ocular surgery.
Durezol (difluprednate ophthalmic emulsion) 0.05%, a topical ophthalmic corticosteroid, has just received approval after priority review by the Food & Drug Administration. Sirion Therapeutics, the maker of the product, claims it’s the first ophthalmic steroid to be indicated for the treatment of both postoperative inflammation and pain associated with ocular surgery. The Tampa, Fla.,
Recent Videos
Related Content
Q&A: Factors Showing Tirzepatide is More Beneficial Than Semaglutide | ASHP Midyear
Brian Nowosielski;Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP;Ashley Gallagher
January 7th 2025Article
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed the benefits of tirzepatide compared with semaglutide.
